Redundancies announced at Stevenage’s GlaxoSmithKline

PUBLISHED: 08:30 17 April 2019

Redundancies are being made at GlaxoSmithKline as part of a new approach to research and development.

Redundancies are being made at GlaxoSmithKline as part of a new approach to research and development.

Archant

Redundancies are being made at pharmaceutical giant GlaxoSmithKline in Stevenage as part of “a new approach to research and development”.

A spokesman for GSK on the Gunnels Wood Road site said “a small number of roles will be directly impacted”.

She said: “Since we announced our new approach to research and development in 2018, the future direction of our portfolio has become clearer, prioritising innovation and moving towards delivering a pipeline of transformational medicines with a focus on immunology, genetically validated targets, and finding platforms and technologies that amplify our science.

“We have identified where changes are necessary to ensure we can fully support our evolving pipeline priorities. We anticipate a small number of roles will be directly impacted by these changes but continue to expect GSK's R&D operations to grow overall with increased investment.”

Become a supporter

This newspaper has been a central part of community life for many years, through good times and bad. Coronavirus is one of the greatest challenges our community has ever faced, but if we all play our part we will defeat it. We're here to serve as your advocate and trusted source of local information.

In these testing times, your support is more important than ever. Thank you.

Most Read

Most Read

Latest from the The Comet